Latest Regulatory Milestones News

Argenica Therapeutics has passed a critical FDA genotoxicity test for its stroke drug ARG-007, advancing its IND application and edging closer to Phase 2b clinical trials in the US and Australia.

Terrain Minerals is progressing steadily towards a maiden Mineral Resource Estimate (MRE) for its Lightning Gold Project, targeting July 2026. Key technical and regulatory milestones are being ticked off, underpinning the project’s transition from exploration to resource definition.

BLIS Technologies posted a 16% revenue increase to $14.7 million in FY26, resolving a key intellectual property dispute and expanding strategic partnerships, including an extended Probi AB agreement that now covers pet nutrition.

Patrys has appointed CMAX and Alithia Life Sciences to lead its Phase 1A clinical trial operations for RLS-2202, advancing its injectable quetiapine program toward first-in-human testing in Q3 2026, pending ethics approval.

OncoSil Medical has clinched TGA approval for its OncoSil™ device, the first Class III medical device targeting pancreatic tumours in Australia, paving the way for local commercialisation and enhanced patient access.

Island Pharmaceuticals has appointed Mark Herzog as Senior Global Health Security Advisor and secured roles in key Medical Countermeasures Coalition groups, boosting its US biodefence engagement ahead of pivotal Galidesivir Animal Rule studies.

Lumos Diagnostics advances US commercial rollout of FebriDx with positive reimbursement data and expanded urgent care adoption ahead of the 2027/28 flu season.

Condor Energy has submitted its application to convert the offshore Tumbes Basin TEA 86 into a Licence Contract, securing 100% ownership and expanding its prospective resources to over 3.3 billion barrels of oil and 1 Tcf of gas.

Pioneer Minerals has appointed Alaska Midnight Sun Drilling for its first reverse circulation drill campaign at the Springfield Tungsten, Gold and Gallium Project in Idaho, targeting high-grade multi-commodity mineralisation in Q3 2026.

Saluda Medical’s Australian arm has secured ASIC approval to bypass standalone audited financial reports, cutting costs and streamlining compliance.

Pacific Edge edges closer to a Medicare breakthrough with a draft Local Coverage Determination proposing coverage for its Cxbladder Triage and Triage Plus tests, potentially unlocking reimbursement for over 66 million US patients.

Lumos Diagnostics has reached a key enrolment milestone in its BARDA-backed FebriDx paediatric trial, unlocking a US$670,000 payment and advancing its FDA submission pathway to expand use in children aged 2-12 years.